Product Description: Venadaparib (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib does not sensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSB) and can be used for solid tumors research[1][2].
Applications: Cancer-programmed cell death
Formula: C23H23FN4O2
References: [1]Yong Man Kim, et al. First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 39, no. 15_suppl (May 20, 2021) 3107-3107./[2]Myongjae Lee, et al. Abstract A106: Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor. American Association for Cancer Research, 2018.
CAS Number: 1681017-83-3
Molecular Weight: 406.45
Compound Purity: 98.11
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: PARP
Deutsch
English
